Overview

Pilot Study of Abemaciclib With Bevacizumab in Recurrent Glioblastoma Patients With Loss of CDKN2A/B or Gain or Amplification of CDK4/6

Status:
Recruiting

Trial end date:
2022-10-24

Target enrollment:

Participant gender:

Summary

Describe the safety and adverse events associated with Abemaciclib 150 mg orally twice daily when administered with Bevacizumab 10 mg/kg intravenously every 2 weeks to recurrent GBM patients with specific tumor molecular aberrations

Phase:

Early Phase 1

Details

Lead Sponsor:

Edward Pan
University of Texas Southwestern Medical Center

Treatments:

Bevacizumab